Cargando…
The prognostic value of TPM1–4 in hepatocellular carcinoma
BACKGROUND: Despite advances in multiple disciplinary diagnoses and treatments, the prognosis of hepatocellular carcinoma (HCC) remains poor. Some evidence has identified that the aberrant expression of tropomyosins (TPMs) is involved with some cancers development. However, prognostic values of TPMs...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729055/ https://www.ncbi.nlm.nih.gov/pubmed/34850589 http://dx.doi.org/10.1002/cam4.4453 |
_version_ | 1784626859412029440 |
---|---|
author | Tian, Zhihui Zhao, Jian Wang, Yusheng |
author_facet | Tian, Zhihui Zhao, Jian Wang, Yusheng |
author_sort | Tian, Zhihui |
collection | PubMed |
description | BACKGROUND: Despite advances in multiple disciplinary diagnoses and treatments, the prognosis of hepatocellular carcinoma (HCC) remains poor. Some evidence has identified that the aberrant expression of tropomyosins (TPMs) is involved with some cancers development. However, prognostic values of TPMs in HCC have not been thoroughly investigated. METHODS: Original TPM1–4 mRNA expression of TCGA HCC data and GTEx was downloaded from UCSC XENA. Oncomine database and GSE46408 were used for verification. Clinical stages and survival analysis of TPM1–4 in HCC were performed by GEPIA2. cBioPortal was utilized to assess TPM1–4 gene alteration in HCC. TIMER2.0 was used for investigating the relevance of TPM1–4 to tumor‐infiltrating immune cells in HCC. Additionally, we constructed a TPM1–4 prognostic model to explore the value of TPM1–4 for prognostic evaluation in HCC. LinkedOmics was applied to elucidate TPM3 co‐expression networks in HCC. RESULTS: This present study showed that TPM1–4 was upregulated in all HCC tissues, and TPM3 overexpression was correlated with poor survival outcomes in patients with HCC. Besides, TPM3 amplification was the main altered type in TPM1–4 genetic alteration, which affected the prognosis of HCC patients. The risk model revealed that TPM1, TPM2, and TPM3 were applied to risk assessment of HCC prognosis, among which TPM3 expression was significantly higher in the high‐risk group than that in the low‐risk group. Univariate and multivariate cox regression analyses indicated that TPM3 may be an independent prognostic factor of HCC prognosis. In addition, TPM3 co‐expression genes mainly participated in the cell cycle by maintaining microtubule cytoskeleton in HCC progression. TPM1–4 was associated with some tumor‐infiltrating immune cells in HCC. CONCLUSION: Our study detected that the expression level of TPM1–4 was all remarkably elevated in HCC, suggesting that TPM1–4 may serve an important role in HCC development. High TPM3 expression was found to be correlated with poor overall survival, and TPM3 may be an independent prognostic factor for HCC. |
format | Online Article Text |
id | pubmed-8729055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87290552022-01-11 The prognostic value of TPM1–4 in hepatocellular carcinoma Tian, Zhihui Zhao, Jian Wang, Yusheng Cancer Med Clinical Cancer Research BACKGROUND: Despite advances in multiple disciplinary diagnoses and treatments, the prognosis of hepatocellular carcinoma (HCC) remains poor. Some evidence has identified that the aberrant expression of tropomyosins (TPMs) is involved with some cancers development. However, prognostic values of TPMs in HCC have not been thoroughly investigated. METHODS: Original TPM1–4 mRNA expression of TCGA HCC data and GTEx was downloaded from UCSC XENA. Oncomine database and GSE46408 were used for verification. Clinical stages and survival analysis of TPM1–4 in HCC were performed by GEPIA2. cBioPortal was utilized to assess TPM1–4 gene alteration in HCC. TIMER2.0 was used for investigating the relevance of TPM1–4 to tumor‐infiltrating immune cells in HCC. Additionally, we constructed a TPM1–4 prognostic model to explore the value of TPM1–4 for prognostic evaluation in HCC. LinkedOmics was applied to elucidate TPM3 co‐expression networks in HCC. RESULTS: This present study showed that TPM1–4 was upregulated in all HCC tissues, and TPM3 overexpression was correlated with poor survival outcomes in patients with HCC. Besides, TPM3 amplification was the main altered type in TPM1–4 genetic alteration, which affected the prognosis of HCC patients. The risk model revealed that TPM1, TPM2, and TPM3 were applied to risk assessment of HCC prognosis, among which TPM3 expression was significantly higher in the high‐risk group than that in the low‐risk group. Univariate and multivariate cox regression analyses indicated that TPM3 may be an independent prognostic factor of HCC prognosis. In addition, TPM3 co‐expression genes mainly participated in the cell cycle by maintaining microtubule cytoskeleton in HCC progression. TPM1–4 was associated with some tumor‐infiltrating immune cells in HCC. CONCLUSION: Our study detected that the expression level of TPM1–4 was all remarkably elevated in HCC, suggesting that TPM1–4 may serve an important role in HCC development. High TPM3 expression was found to be correlated with poor overall survival, and TPM3 may be an independent prognostic factor for HCC. John Wiley and Sons Inc. 2021-11-30 /pmc/articles/PMC8729055/ /pubmed/34850589 http://dx.doi.org/10.1002/cam4.4453 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Tian, Zhihui Zhao, Jian Wang, Yusheng The prognostic value of TPM1–4 in hepatocellular carcinoma |
title | The prognostic value of TPM1–4 in hepatocellular carcinoma |
title_full | The prognostic value of TPM1–4 in hepatocellular carcinoma |
title_fullStr | The prognostic value of TPM1–4 in hepatocellular carcinoma |
title_full_unstemmed | The prognostic value of TPM1–4 in hepatocellular carcinoma |
title_short | The prognostic value of TPM1–4 in hepatocellular carcinoma |
title_sort | prognostic value of tpm1–4 in hepatocellular carcinoma |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729055/ https://www.ncbi.nlm.nih.gov/pubmed/34850589 http://dx.doi.org/10.1002/cam4.4453 |
work_keys_str_mv | AT tianzhihui theprognosticvalueoftpm14inhepatocellularcarcinoma AT zhaojian theprognosticvalueoftpm14inhepatocellularcarcinoma AT wangyusheng theprognosticvalueoftpm14inhepatocellularcarcinoma AT tianzhihui prognosticvalueoftpm14inhepatocellularcarcinoma AT zhaojian prognosticvalueoftpm14inhepatocellularcarcinoma AT wangyusheng prognosticvalueoftpm14inhepatocellularcarcinoma |